IRX Therapeutics Announces That Jean Louis Lefebvre, M.D. Has Joined Its Medical Advisory Board.NEW YORK New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of -- IRX IRX Information Retrieval Experiment IRX Interactive Resources Executive Therapeutics, a privately-held company dedicated to the development and commercialization of novel drugs for the treatment of cancer and viral diseases, today announced that Jean Louis Lefebvre, M.D., ENT ENT ears, nose, and throat (otorhinolaryngology). ENT abbr. ear, nose, and throat ENT ear, nose and throat. ENT Ears, nose & throat; formally, otorhinolaryngology and Head and Neck Surgeon has joined its Medical Advisory Board. Dr. Jean Louis Lefebvre, a global leader in the field of Head and Neck Cancer, is the Head of the Department of Otolaryngology, Head and Neck Surgery, Centre Oscar Lambret, Lille, France. In 1976, he joined the Centre Oscar Lambret, the Northern France Comprehensive Cancer Center, and became Chief of the Department in 1994. He served as Deputy Director of the Center (1996-2001) and was elected President of its Medical Commission (2003-2006). "We are pleased to welcome Dr. Lefebvre to our Medical Advisory Board." said John W. Hadden, M.D., Founder and Chief Scientific Officer. "Dr. Lefebvre's European expertise will complement that of the existing Medical Advisory Board which includes U.S.-based leaders in the field of head and neck cancer. We look forward to working with him as we expand our planning of the IRX-2 clinical trial to include global sites." In addition to Dr. Lefebvre's work at Centre Oscar Lambret, he chaired the EORTC EORTC European Organization for Research and Treatment of Cancer HNC (HNC Software Inc., San Diego, CA) A software company that specialized in products that detect credit card fraud, manage merchant risk, automate lending decisions and home valuations and manage retail inventories. Founded in 1986 by Robert Hecht-Nielsen and Todd W. Group (1989-1998) and was a member of the EORTC Board (1997-1999). He has been appointed as the Secretary General (2003-2006) and Director (2006- ) of the International Federation of Head and Neck Oncology Societies, President of the Founding Board of the European Head and Neck Society (2003- ) and Vice President of the International Academy of Oral Oncology (2005- ). He is a member of twenty-three Head and Neck societies and is involved in twenty-four scientific journals either as a member of the editorial board or as a reviewer. In 1995, Dr. Lefebvre received the Special Recognition Award of the Society of Head and Neck Surgeons. The Company's ongoing Phase 2 trial of IRX-2, it's lead immunotherapeutic cancer drug targeted at treating head and neck cancer, is being managed by Quintiles Quintiles Transnational Corp. is a contract research organization which serves the pharmaceutical, biotechnology and healthcare industries. History Quintiles was founded in 1982 by Dennis Gillings and as of 2007 it has 18,000 employees. Transnational Corp. Quintiles is the global leader in pharmaceutical services, improving healthcare worldwide by providing innovative, quality professional expertise, market intelligence and partnering solutions to meet the dynamic needs of the pharmaceutical, biotechnology and healthcare industries. Quintiles has 16,000 specialized employees and offices in more than 50 countries. More information about this Phase 2 trial can be found at http://www.clinicaltrials.gov. IRX Therapeutics discovers and develops therapeutic treatments that act on multiple cellular targets to restore the immune system's ability to treat cancer and viral diseases. IRX-2 seeks to correct both dendritic cell dendritic cell n. 1. A cell that has branching processes. 2. Any of the cells in the neural crest of the embryonic ectoderm having extensive processes and developing early as producers of melanin. and T-cell defects to stimulate an immune response immune response n. An integrated bodily response to an antigen, especially one mediated by lymphocytes and involving recognition of antigens by specific antibodies or previously sensitized lymphocytes. to destroy tumor cells. IRX-2 received Fast Track designation by the Food and Drug Administration in November of 2003. An open label Phase 2 clinical trial phase 2 clinical trial Phase 2 study. See Phase study. in late-stage head and neck cancer patients was completed which demonstrated statistically significant improvement in the treatment group and a clinical response rate of 38%. After forty-eight months, the overall survival of IRX-2 treated patients was 61% versus 32% for the concurrent institutional control group. About IRX Therapeutics IRX Therapeutics is a privately held immunotherapy company focusing on the development and commercialization of treatments for advanced cancer and viral diseases. Founded in 1994 by John W. Hadden, M.D., a pioneer in the field of Immunopharmacology, IRX Therapeutics is developing an innovative approach that stimulates a coordinated cellular immune response cellular immune response n. See cell-mediated immune response. to treat human diseases. The Company's product pipeline includes IRX-2, a therapeutic cancer therapy that seeks to stimulate a cellular immune response in the host to destroy tumor cells. Other products in development similarly seek to stimulate a cellular immune response for the treatment of other cancers and viral diseases. This immune response is essential for the eradication of most viruses and tumors, and relies on the effective functioning of dendritic cells, macrophages Macrophages White blood cells whose job is to destroy invading microorganisms. Listeria monocytogenes avoids being killed and can multiply within the macrophage. , and T-cells. For more information on IRX Therapeutics, please visit the Company's website at http://www.irxtherapeutics.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion